As the European branch of BGI, BGI Europe was founded on May 17th, 2010 in Denmark, with a mission of partnering with researchers and scientists in Europe and contributing to the advancement of innovative biology research, molecular breeding, healthcare and related fields. BGI-Europe is dedicated to facilitate the applications in Healthcare, Agriculture, and the Environment, to give people a better life.

BGI Europe research center

BGI Europe research center was launched in 2011, located at the Copenhagen Bio Science Park (COBIS), a technology cluster in the capital of Denmark. The laboratory center covers 1,200 square meters, and has been equipped with 10 Illumina HiSeq 2000 sequencers.

BGI Tech Europe is the European branch of BGI Tech. We provide comprehensive sequencing and bioinformatics services for medical, agricultural and environmental applications. BGI Tech Europe is committed to helping our customers achieve their research goals by delivering rapid, high-quality results using a broad array of cost-effective, cutting-edge technologies. Our service network covers over 30 countries in Europe, including Denmark, Sweden, United Kingdom, France, Norway, Finland, Germany, Spain, Turkey, Slovenia, Italy, The Netherlands, Russia, etc. 

Currently, BGI-Tech collaborates with over 10,000 organizations and 30,000 partners, providing highly reliable services for thousands of research projects, including several large-scale international genome projects. We strive to accelerate the advancement of life science industry and to assist in the fight against various health, agricultural, energy, and environmental issues to create a better life and a brighter future for people.

For more information, please .

The Genetic Testing of BGI Europe is provided by BGI Diagnostics Europe.  BGI Diagnostics is a subsidiary unit of BGI, one of the largest genomics research organizations in the world. The aim of BGI Diagnostics is to apply its high genetic research capacity and network into solving current health issues worldwide. BGI Diagnostics commits to reducing the rate of birth defects and major diseases by offering a broad array of accurate, reliable and affordable genetic tests and molecular diagnostics services.

The focuses of BGI Diagnostics include the detection of birth defects and various genetic disorders. These disorders include various chromosome diseases, monogenic disorder, hereditary hearing loss, and neonatal hereditary metabolic diseases. Hereditary cancer (breast, ovarian prostate cancer), medication instruction for target/chemo therapy, MODY (maturity onset diabetes of the young) and cystic fibrosis will be the current major focus.

The flagship product, NIFTYTM (Non-Invasive Fetal TrisomY test) is a non-invasive prenatal test, which examines peripheral blood from the mother to estimate the risk of fetal chromosomal aneuploidies carried in the unborn. Detecting aneuploidies in the fetus allows early preparation and intervention. NIFTY test is the most validated on the market, as proven by a published clinical study involving more than 11,000 pregnant women. Over 20,000 NIFTY tests have been performed across Europe by the end of 2013.

For more information about BGI Diagnostics, please visit

In the past three years, BGI Europe has established partnerships and collaborations with leading European academic and governmental research institutions as well as global biotechnology and pharmaceutical companies. Among the more recent partnerships and collaborations entered into by BGI Europe include:

1. Collaboration with he University of Copenhagen, the Technical University of Denmark, Aarhus University and Aalborg University have--received the largest grant ever awarded by the Danish National Advanced Technology Foundation--to establish a national technology platform that will facilitate the mapping of the Danish genome.

2. Gathering 9 Danish university centers/institutes in LUCAMP Project, in the purpose of clinical translation of research discoveries to patients for new personalized interventions and ongoing large-scale observational studies and clinical trials.

3. Collaboration with TwinsUK, launched the Largest Ever Epigenetics Projectin Human Genetics to mark the differences between 5,000 twins on a scale and depth never before attempted, providing key therapeutic targets for the development of drug treatments.

4. Collaboration with the University Medical Centre Hamburg-Eppendorf carried out research to combat German deadly E. coli, and rapidly released theopen-source genomic data. The study was published in The New England Journal of Medicine (NEJM), revealing for the first time that rapid open-source analysis of an outbreak-associated bacterial pathogen can play a significant role in public health emergencies.

5. Memorandum of Understanding (MOU) with Technological Top Institute of Green Genetics (TTI GG), Netherlands eScience Centre (NLeSC), and Netherlands Institute of Bioinformatics (NBIC) to address the challenge of managing, transporting, integrating and analysing today’s tremendous flow of genomic data.

6. Agreement with Novo Nordisk to establish Global Collaboration Framework

Through its growing presence in Europe, BGI Europe is prepared to establish more partnerships with communities and promote scientific advances with state-of-the-art sequencing technologies and value-added bioinformatic analytics.

7. Jointly complete the "Genome of The Netherlands Project" with The Genome of the Netherlands consortium, this project offers unique opportunities for science and for the development of new treatments and diagnostic techniques.

8. Initiate 100 Tomato Genome Project with TTI GG (Technological Top Institute Green Genetics), it is a joint Sino-Dutch research project on data generation and data exploitation on the basis of 100 (a hundred) tomato genomes. The project will provide a significant scientific value for raising tomato production with high yields and good quality, and also contributes to studies on integrated control of tomato diseases and pests.